Emerging pharmacological strategies for treating and preventing mpox.

Abstract

INTRODUCTION:

Since May 2022, there have been nearly 87,000 documented cases of mpox worldwide, with 119 deaths. Pharmacological interventions for mpox include the MVA-BN smallpox vaccine, tecovirimat, cidofovir, its pro-drug brincidofovir, and vaccinia immune globulin intravenous (VIGIV).

AREAS COVERED:

The literature search and information gathering for this review included the PubMed database focusing on mpox and monkeypox, in combination with tecovirimat, brincidofovir, cidofovir, VIGIV, and smallpox vaccine. WHO.int, CDC.gov, FDA.gov, and ClinicalTrials.gov websites were accessed for the most recent information on the mpox outbreak. Mechanisms for deployment and access to treatment including expanded access, emergency use, and clinical trials will be discussed. Treatment outcomes with safety data will be presented.

EXPERT OPINION:

The vaccine as a preventive measure, along with numerous treatment options, largely controlled the outbreak, although deployment of each could be improved upon to hasten and broaden access. More widespread coverage by the vaccine is necessary to prevent future resurgence of mpox. Tecovirimat has emerged as a safe frontline treatment for mpox, while brincidofovir use has been limited by safety concerns. VIGIV and cidofovir should be reserved for the most severe cases in which other options are not fully effective.

• Authors: Douglas W Grosenbach, Andrew T Russo, Emily D Blum, Dennis E Hruby
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) 2023 Jul-Dec Vol. 16 Issue 9 Pg. 843-854 ISSN: 1751-2441 [Electronic] England
• PMID: 37592723 (Publication Type: Journal Article, Review)

Chemical References

• Cidofovir
• brincidofovir
• human intravenous vaccinia immune globulin
• Benzamides
• Vaccines

Topics

• Humans
• Cidofovir
• Monkeypox
• Benzamides
• Vaccines